Showing all posts written by Robert Hilton
Dr. Hilton earned his J.D. at the J. Reuben Clark Law School at Brigham Young University. While in law school, Dr. Hilton was the president of the Student Intellectual Property Law Association. Dr. Hilton worked at the University Technology Transfer Office during law school, where he gained experience with patent protection and technology licensing.
Prior to attending law school, Dr. Hilton earned his Ph.D. in biochemistry. Dr. Hilton's research involved the studies of metals in biological systems. This work required an in depth understanding and training in a variety of chemistry biochemisty techniques such as electron microscopy, ICP-MS, PCR, cell culture, protein purification, and gel electrophoresis.
Dr. Hilton was a summer associate for the firm in 2013, and joined the firm in 2014. Click here to read full bio
On July 20, 2017, the Food and Drug Administration announced the clearance of “the first magnetic resonance imaging (MRI) device specifically for neonatal brain and head imaging in neonatal intensive care units (NICU)” to
On April 12, 2017, the Federal Circuit affirmed the determination by the US Patent and Trademark Office (USPTO), Patent Trial and Appeal Board (Board) that the claims of U.S. Patent No. 8,324,283 (“the ’283 patent”) were invalid
Salt Lake City-based Myriad Genetics, Inc. announced that its BRACAnalysis CDx® test accurately identifies patients with ovarian cancer for a second-line treatment with olaparib. The announcement came as a result of a clinical study
GlaxoSmithKline (GSK) announced that it is partnering with Verily Life Sciences LLC to form Galvani Bioelectronics. According to the press release, GSK and Verily will contribute IP rights and an investment of $712.7 million over seven
Lake Forest, Illinois-based RoundTable Healthcare Partners recently announced an agreement to acquire Symmetry Surgical, Inc. RoundTable states that the acquisition will provide a new platform in surgical instrumentation and specialty
West Chester, Pennsylvania-based Animas Corporation recently announced FDA approval for the use of the Animas® Vibe® Insulin Pump and Continuous Glucose Monitoring (CGM) System for children and adolescents, ages two to seventeen.